[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kailera Therapeutics Inc (KLRA)

Kailera Therapeutics Inc (KLRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,697,564
  • Shares Outstanding, K 129,566
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,960 K
  • EBIT $ -105 M
  • EBITDA $ -105 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3,650.00
  • Most Recent Earnings N/A on 05/26/26
  • Next Earnings Date 08/25/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 2
  • High Estimate $-0.67
  • Low Estimate $-0.80
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.50 +12.54%
on 06/16/26
23.98 -13.18%
on 06/02/26
-2.36 (-10.18%)
since 06/01/26

Most Recent Stories

More News
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment...

CMPS : 13.29 (-6.08%)
KLRA : 20.82 (-5.49%)
SPRO : 2.22 (+0.45%)
How to Play PBLS Stock After the Parabilis IPO

Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.

KLRA : 20.82 (-5.49%)
PBLS : 27.76 (+1.42%)
MRNA : 72.50 (+3.53%)
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight...

KLRA : 20.82 (-5.49%)
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that...

KLRA : 20.82 (-5.49%)
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection...

KLRA : 20.82 (-5.49%)
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc....

KLRA : 20.82 (-5.49%)
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

KLRA : 20.82 (-5.49%)
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care,...

KLRA : 20.82 (-5.49%)
Kailera Therapeutics Announces Pricing of Initial Public Offering

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care,...

KLRA : 20.82 (-5.49%)

Key Turning Points

3rd Resistance Point 24.13
2nd Resistance Point 23.26
1st Resistance Point 22.04
Last Price 20.82
1st Support Level 19.95
2nd Support Level 19.08
3rd Support Level 17.86

See More

52-Week High 28.23
Fibonacci 61.8% 24.51
Fibonacci 50% 23.36
Fibonacci 38.2% 22.22
Last Price 20.82
52-Week Low 18.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.